Astellas Pharma Inc. (ALPMF) Q4 2024 Earnings Call Transcript

featured-image

Astellas Pharma Inc. ( OTCPK:ALPMF ) Q4 2024 Earnings Conference Call April 25, 2025 4:00 AM ET Company Participants Hiromitsu Ikeda - Chief Communications and IR Officer Naoki Okamura - Representative Director, President & Chief Executive Officer Claus Zieler - Chief Commercial Officer & Medical Affairs Officer Tadaaki Taniguchi - Chief Medical Officer Atsushi Kitamura - Chief Financial Officer Conference Call Participants Hidemaru Yamaguchi - Citigroup Securities Seiji Wakao - JPMorgan Securities Akinori Ueda - Goldman Sachs Securities Shinichiro Muraoka - Morgan Stanley MUFG Securities Hiroyuki Matsubara - Nomura Securities Miki Sogi - Sanford C. Bernstein Kazuaki Hashiguchi - Daiwa Securities Fumiyoshi Sakai - UBS Securities Hiromitsu Ikeda Thank you very much for joining our FY 2024 Financial Results Announcement Meeting by Astellas Pharma Inc.

out of your very busy schedule today. I'm delighted to serve as a moderator. I'm Ikeda, Chief Communications and IR Officer.



Thank you for your time. Today after presentation, we move on to Q&A session. Presentation will be made based on the material posted on our website under the IR Meeting Section.

We have simultaneous translation between Japanese and English including Q&A. We cannot guarantee the accuracy of the translation. Thank you for understanding.

You can choose the language from the menu on the Zoom webinar screen. If you select the original language, you can listen to the original sound without going through the translation. Disclaimer for today, this material or representation by representatives for the company, and their answers and statement in the Q&A session includes forward-looking statements based on assumptions and beliefs in light of the information currently available to management and subject to significant risks and uncertainties.

Actual financial results may differ materially depending on a number of factors. They contain information on pharmaceuticals, including compounds under development, but this information is not intended to make any representations or advertisements.